Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» diffuse systemic sclerosis
diffuse systemic sclerosis
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
Drugs.com
Wed, 04/16/25 - 10:55 pm
Allogene
FDA
CAR-T
fast track
ALLO-329
systemic lupus erythematosus
idiopathic inflammatory myopathy
diffuse systemic sclerosis
